Posted by Michael Wonder on 19 Jan 2022
Beyond survival: the US FDA confirms surrogate end points for patients with newly diagnosed acute myeloid leukaemia treated with intensive chemotherapy
10 January 2022 - The treatment of acute myeloid leukaemia has rapidly evolved over the past decade.
On the basis of an improved scientific understanding of leukaemia pathophysiology and impressive translational development programs, multiple new therapeutic options are now available for our patients.
